{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:53:01Z","timestamp":1758703981427},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T00:00:00Z","timestamp":1379548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40257-013-0045-5","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T09:58:39Z","timestamp":1379498319000},"page":"461-471","source":"Crossref","is-referenced-by-count":10,"title":["Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset"],"prefix":"10.1007","volume":"14","author":[{"given":"Dan C.","family":"Filitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Mahalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"key":"45_CR1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol."},{"key":"45_CR2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707\u201314.","journal-title":"N Engl J Med."},{"key":"45_CR3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354.","journal-title":"Nature"},{"key":"45_CR4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855\u201367.","journal-title":"Cell"},{"key":"45_CR5","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135\u201347.","journal-title":"N Engl J Med."},{"key":"45_CR6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809\u201319.","journal-title":"N Engl J Med."},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893\u2013901.","journal-title":"Lancet"},{"key":"45_CR8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","volume":"167","author":"RM Anforth","year":"2012","unstructured":"Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153\u201360.","journal-title":"Br J Dermatol."},{"issue":"3","key":"45_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11912-013-0308-6","volume":"15","author":"VR Belum","year":"2013","unstructured":"Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249\u201359.","journal-title":"Curr Oncol Rep."},{"key":"45_CR10","doi-asserted-by":"crossref","unstructured":"Pappas-Taffer L, Rosenbach M, Chu EY. The cutaneous side effects of selective BRAF inhibitors and anti-CTLA4 agents: the growing role of the dermatologist in the management of patients with metastatic melanoma. Curr Dermatol Rep. 2013:1\u201317.","DOI":"10.1007\/s13671-013-0039-9"},{"key":"45_CR11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med."},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","volume":"167","author":"R Sinha","year":"2012","unstructured":"Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167:987\u201394.","journal-title":"Br J Dermatol."},{"key":"45_CR13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","volume":"67","author":"EY Chu","year":"2012","unstructured":"Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67:1265\u201372.","journal-title":"J Am Acad Dermatol."},{"key":"45_CR14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.758","volume":"148","author":"V Huang","year":"2012","unstructured":"Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148:628\u201333.","journal-title":"Arch Dermatol."},{"key":"45_CR15","doi-asserted-by":"crossref","unstructured":"Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, et al. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2012 (Epub ahead of print).","DOI":"10.1093\/annonc\/mds292"},{"key":"45_CR16","first-page":"7","volume":"18","author":"CM Wang","year":"2012","unstructured":"Wang CM, Fleming KF, Hsu S. A case of vemurafenib-induced keratosis pilaris-like eruption. Dermatol Online J. 2012;18:7.","journal-title":"Dermatol Online J"},{"key":"45_CR17","unstructured":"Flaherty KT. Building on BRAF inhibition in melanoma and extending to other cancers. Presented at the ASCO Annual Meeting, Chicago, IL, USA. 2011."},{"key":"45_CR18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archdermatol.2011.3080","volume":"148","author":"A Alloo","year":"2012","unstructured":"Alloo A, Garibyan L, LeBoeuf N, Lin G, Werchniak A, Hodi FS Jr, Flaherty KT, Lawrence DP, Lin JY, et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012;148:363\u20136.","journal-title":"Arch Dermatol."},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1524-4725.2012.02396.x","volume":"38","author":"N Ezra","year":"2012","unstructured":"Ezra N, Hamid O, Behroozan D. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma. Dermatol Surg. 2012;38:1086\u201390.","journal-title":"Dermatol Surg."},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/DAD.0b013e3182604873","volume":"34","author":"NT Harvey","year":"2012","unstructured":"Harvey NT, Millward M, Wood BA. Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol. 2012;34:822\u20136.","journal-title":"Am J Dermatopathol."},{"key":"45_CR21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet."},{"issue":"3","key":"45_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207\u201315.","journal-title":"N Engl J Med."},{"key":"45_CR23","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30:2375\u201383.","journal-title":"J Clin Oncol."},{"key":"45_CR24","unstructured":"Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E\/K) metastatic melanoma. Pigment Cell Melanoma Res. 2011;24:1020 (abstract)."},{"key":"45_CR25","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694\u2013703.","journal-title":"N Engl J Med."},{"key":"45_CR26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","volume":"148","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Livingstone E, Hillen U, et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148:357\u201361.","journal-title":"Arch Dermatol."},{"key":"45_CR27","doi-asserted-by":"crossref","unstructured":"Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691\u20137.","DOI":"10.1093\/annonc\/mdt015"},{"issue":"3","key":"45_CR28","doi-asserted-by":"crossref","first-page":"e58721","DOI":"10.1371\/journal.pone.0058721","volume":"8","author":"JD Rinderknecht","year":"2013","unstructured":"Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, Dummer R, Belloni B. RASopathic skin eruptions during vemurafenib therapy. PLoS One. 2013;8(3):e58721.","journal-title":"PLoS One."},{"issue":"3","key":"45_CR29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314\u201322.","journal-title":"Oncologist."},{"issue":"11","key":"45_CR30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087\u201395.","journal-title":"Lancet Oncol."},{"key":"45_CR31","doi-asserted-by":"crossref","unstructured":"Hauschild A, Grob J-J, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600 E-mutated melanoma. Proc Am Soc Clin Oncol. 2012; 30(suppl): LBA8500 (abstr).","DOI":"10.1200\/jco.2012.30.18_suppl.lba8500"},{"key":"45_CR32","doi-asserted-by":"crossref","unstructured":"Anforth R, Fernandez-Pe\u00f1as P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11\u20138.","DOI":"10.1016\/S1470-2045(12)70413-8"},{"issue":"15","key":"45_CR33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","volume":"365","author":"S Dalle","year":"2011","unstructured":"Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448\u20139.","journal-title":"N Engl J Med."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0045-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-013-0045-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0045-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T01:42:56Z","timestamp":1563932576000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-013-0045-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s40257-013-0045-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}